

Notice of 2026 Annual General Meeting - Clarification

Melbourne, Australia, 23 October 2026: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”), advises further to the release of 4DMedical’s notice of meeting for the upcoming Annual General Meeting (**Meeting**) to be held on Wednesday, 28 October 2026 at 10:00am (AEDT) (**Notice**), the following further details are provided in relation to the implications of Item 6 being tabled at the Meeting, not being passed.

Unless otherwise defined, capitalised terms in this announcement have the same meanings given to them in the Notice.

The Explanatory Statement for Item 6 (Issue of Options to Executive Director and CFO) provides as follows:

- If Item 6 is not passed, “the Company would need to pay \$920,980 in cash to Mr Sutton from its existing cash reserves in respect of Mr Sutton’s short-term incentive entitlements”.

Notwithstanding the above disclosure, the Company confirms it has not entered into any relevant agreement with Mr Sutton, pursuant to which the Company is contractually obliged to pay Mr Sutton the cash equivalent value of any Equity Securities granted to him, in circumstances where the requisite Shareholder approval is not obtained.

If Shareholder approval is not obtained for Item 6, the Company confirms that it will need to consider alternative remuneration arrangements for Mr Sutton consistent with the Company’s remuneration principles, such as providing an equivalent short term and/or long term cash incentive. As at the date of this announcement, no decision has been made by the 4DMedical Board regarding an alternative cash payment to Mr Sutton. Rather, for the purposes of illustrating the equivalent economic outcome that the Company may need to offer to Mr Sutton in such circumstances, the relevant amounts disclosed in the Notice were calculated by multiplying the number of options subject to shareholder approval by the prevailing market price of 4DX shares at 30 June 2026.

The Company confirms that any such alternative remuneration arrangements will be undertaken in accordance with the Company’s obligations under the Corporations Act 2001 (Cth) and the ASX Listing Rules, including compliance with ASX Listing Rule 3.16.4.

Accordingly, for the sake of clarity, the Company provides the following clarifying disclosures regarding the implications of Item 6 not being passed at the Meeting:

- “If Item 6 is not passed, the Company will not be able to proceed with the proposed issue of JS Options to Mr Sutton. In that circumstance, the Company would need to consider offering alternative incentives to Mr Sutton as may be agreed between Mr Sutton and the Company. In lieu of the JS FY26 Options and JS Incentive Options, this may include a cash payment from the Company’s existing cash reserves, which equates to an amount of up to \$920,980 (based on the fair value of the options calculated by reference to the closing price of 4DX shares on 30 June 2026). In lieu of the JS FY27 LTI Options, the Board would then need to consider alternative remuneration arrangements for Mr Sutton consistent with the Company’s remuneration principles, such as providing an equivalent long term cash incentive.”

—ENDS—

Authorised by the 4DMedical Board of Directors.



Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology**® transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS**®), **CT LVAS**™, and the ground-breaking **CT:VQ**® solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalised patient care. With advanced AI capabilities added through its acquisitions of Imbio in 2023 and contextflow in 2026, 4DMedical is redefining how respiratory disease is imaged, understood and treated worldwide.

Learn more at www.4dmedical.com